Who are Simbrinza 0.2%-1% Ophthalmic Suspension's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Brinzolamide/Brimonidine FC, Brinzolamide/brimonidine ophthalmic suspension.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/simbrinza-0-2-1-ophthalmic-suspension.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Simbrinza 0.2%-1% Ophthalmic Suspension — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Simbrinza 0.2%-1% Ophthalmic Suspension (Simbrinza 0.2%-1% Ophthalmic Suspension) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fixed-dose combination of carbonic anhydrase inhibitor and alpha-2 adrenergic agonist. Area: Ophthalmology.

marketed Fixed-dose combination of carbonic anhydrase inhibitor and alpha-2 adrenergic agonist Carbonic anhydrase II; alpha-2 adrenergic receptor Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Simbrinza 0.2%-1% Ophthalmic Suspension (Simbrinza 0.2%-1% Ophthalmic Suspension) — Prairie Eye Center. Simbrinza combines a beta-adrenergic antagonist and a carbonic anhydrase inhibitor to reduce intraocular pressure by decreasing aqueous humor production.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Simbrinza 0.2%-1% Ophthalmic Suspension TARGET	Simbrinza 0.2%-1% Ophthalmic Suspension	Prairie Eye Center	marketed	Fixed-dose combination of carbonic anhydrase inhibitor and alpha-2 adrenergic agonist	Carbonic anhydrase II; alpha-2 adrenergic receptor
Brinzolamide/Brimonidine FC	Brinzolamide/Brimonidine FC	University Hospital of Patras	marketed	Carbonic anhydrase inhibitor / Alpha-2 adrenergic agonist combination	Carbonic anhydrase II; Alpha-2 adrenergic receptor
Brinzolamide/brimonidine ophthalmic suspension	Brinzolamide/brimonidine ophthalmic suspension	Padagis LLC	phase 3	Carbonic anhydrase inhibitor / Alpha-2 adrenergic agonist combination	Carbonic anhydrase II; Alpha-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fixed-dose combination of carbonic anhydrase inhibitor and alpha-2 adrenergic agonist class)

Prairie Eye Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Simbrinza 0.2%-1% Ophthalmic Suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/simbrinza-0-2-1-ophthalmic-suspension. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab